Scanning the horizon for high value-add manufacturing science: Accelerating manufacturing readiness for the next generation of disruptive, high-value curative cell therapeutics
Since the Regenerative Medicine sector entered the second phase of its development (RegenMed 2.0) more than a decade ago, there is increasing recognition that current technology innovation trajectories will drive the next translational phase towards the production of disruptive, high value curative...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Default Article |
| Published: |
2018
|
| Subjects: | |
| Online Access: | https://hdl.handle.net/2134/28153 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|